news Cases with the TMPRSS2-ERG fusion did not exhibit reduced prostate cancer survival (HR=0.92, 95% CI=0.22-3.93), nor was there a significant difference in cause-specific survival when stratifying by translocation or deletion (HR=0.84, 95% CI=0.23-3.12) or by the number of retained fusion copies (HR=1.22, 95% CI=0.45-3.34). However, evidence for reduced prostate cancer-specific survival was apparent in those cases whose tumor had multiple copies of the fusion.
The variant T allele of the TMPRSS2 SNP, rs12329760, was positively associated with TMPRSS2-ERG fusion by translocation (p=0.05) and with multiple copies of the gene fusion (p=0.03).
Conclusion: If replicated, the results presented here may provide insight into the mechanism by which the TMPRSS2-ERG gene fusion arises and also contribute to diagnostic evaluations for determining the subset of men who will go on to develop metastatic prostate cancer. prostate cancer T allele appears to have lower survival, and higher recurrence.
[PMID 18694509
] Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.
[PMID 30505817] Status of TMPRSS2-ERG fusion in prostate cancer patients from India: correlation with clinico-pathological details and TMPRSS2 Met160Val polymorphism.
] Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.
